Ardelyx Inc (ARDX.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|51||2014||Independent Chairman of the Board|
|52||2009||President, Chief Executive Officer, Director|
|49||2017||Chief Financial Officer, Principal Accounting Officer|
|45||2016||Chief Operating Officer, Executive Vice President|
|48||2014||Executive Vice President, Chief Scientific Officer|
- BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
- BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia
- BRIEF-Ardelyx qtrly net loss per common share $0.44
- BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing
- BRIEF-Ardelyx announces Tenapanor reduces pain caused by IBS-C through inhibition of TRPV-1 signaling